REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Feb 24, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-02-23

Reporting Person: SHOOTER ERIC M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-02-23	Common Stock	C	10000	—	Acquired	10000	Indirect
2012-02-23	Common Stock	S	9600	$103.51	Disposed	400	Indirect
2012-02-23	Common Stock	S	400	$104.05	Disposed	0	Indirect
2012-02-23	Common Stock	C	10000	—	Acquired	10000	Indirect
2012-02-23	Common Stock	S	9600	$103.51	Disposed	400	Indirect
2012-02-23	Common Stock	S	400	$104.05	Disposed	0	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-02-23	Class A Stock	$0	C	10000	Disposed		Common Stock (10000)	Indirect
2012-02-23	Class A Stock	$0	C	10000	Disposed		Common Stock (10000)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Class A Stock	$0		Common Stock (36911)	36911	Indirect

Footnotes

F1: Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events.

F2: Represents volume-weighted average price of sales of 9,600 shares of Company stock on February 23, 2012 at prices ranging from $103.01 to $103.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the GRAT on February 23, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 400 shares of Company stock on February 23, 2012 at prices ranging from $104.01 to $104.12. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the GRAT on February 23, 2012 at each separate price.

F4: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

F5: The reporting person and his spouse are co-trustees and beneficiaries of the Shooter Family Trust.